Acupuncture and moxibustion treatment for Crohn's disease

Study on the regulatory mechanism of acupuncture and moxibustion on autophagy mediated by chromatin remodeling in Crohn's disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN38009074

Enrollment

Registered

2017-02-21

Start date

2017-02-20

Completion date

Unknown

Last updated

2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease Digestive System Crohn's Disease

Interventions

Participants are randomly allocated to one of two groups. Randomisation is conducted using a computer-generated numbers placed sequentially in envelopes and kept by a clinician with no contact to the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Crohn's disease 2. Aged 16-70 3. Patients with mild or moderate CD (CDAI between 151 and 450) 4. Not taking any medication or taking mesalazine, prednisone, immunosuppressive drugs 5. Did not take or no longer taking biological agents such as infliximab 6. Signed informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients 2. Associations with heart, brain, liver, kidney and hematopoietic system of serious diseases 3. Mental illness or other serious diseases 4. Presence of skin disease, fistula, sinus, mutilation and other conditions in the acupoints selected in the study that can not be implemented moxibustion treatment 5. Taking other medications that can lead to a CD symptom aggravating or changing the efficacy of drugs 6. Associations with short bowel syndrome, symptoms of intestinal stenosis, 7. Previous stomach or gastrointestinal tract surgery

Design outcomes

Primary

Measure	Time frame
Disease severity is measured using the Crohn's disease activity index (CDAI) at baseline, 6, 12 and 24 weeks.	—

Secondary

Measure	Time frame
1. Quality of life is measured using the Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline, 12 and 24 weeks 2. Psychological factors are measured using the Hospital anxiety and depression scale (HADS) at baseline, 12 and 24 weeks 3. Disease activity are measured using blood (C-reaction protein, Erythrocyte sedimentation rate, blood platelet) at baseline,12 and 24 weeks 4. Endoscopic findings are measured using the Simple Endoscopic Score for Crohn's Disease (SES-CD) at baseline and 48 weeks 5. Pathogenic manifestations are measured using the Histological techniques (Hematoxylin-eosin staining and Histological scores) at baseline and 48 weeks 6. Immunity-related issues are measured using the protein and messenger ribonucleic acid (mRNA) expression of autophagy related protein 16 like protein 1(ATG16L1), immunity-related GTPase family M protein (IRGM), and interleukin-18 at baseline, 12 and 24 weeks	—

Measure

Time frame

1. Quality of life is measured using the Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline, 12 and 24 weeks 2. Psychological factors are measured using the Hospital anxiety and depression scale (HADS) at baseline, 12 and 24 weeks 3. Disease activity are measured using blood (C-reaction protein, Erythrocyte sedimentation rate, blood platelet) at baseline,12 and 24 weeks 4. Endoscopic findings are measured using the Simple Endoscopic Score for Crohn's Disease (SES-CD) at baseline and 48 weeks 5. Pathogenic manifestations are measured using the Histological techniques (Hematoxylin-eosin staining and Histological scores) at baseline and 48 weeks 6. Immunity-related issues are measured using the protein and messenger ribonucleic acid (mRNA) expression of autophagy related protein 16 like protein 1(ATG16L1), immunity-related GTPase family M protein (IRGM), and interleukin-18 at baseline, 12 and 24 weeks

—

Countries

China

Contacts

Public ContactBao;Shi Chunhui;Yin

;

baochunhui789@126.com;flysy0636@hotmail.com+86 21 64395973;+86 21 64383910

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026